Krystal Biotech (KRYS) Stock Looks Stretched Against Current Earnings Power

Krystal Biotech has rewarded long term holders with very strong gains, which puts a sharper spotlight on whether the current share price lines up with what its earnings can reasonably support. With the stock recently closing at US$344.96, the question for you is how much of that move is grounded in the underlying profit power of the business.

• Over the past 5 years the stock has delivered a very large total return, so any fresh money going in today is taking a view on how sustainable the earnings story really is.
• The business model depends heavily on how efficiently research spending and commercialization can be turned into durable profits, which can influence both earnings quality and the timing of future cash generation.
• Your read on Krystal Biotech is one view; the desks covering it have another. See what analysts think Krystal Biotech's shares could be worth.

For investors, the debate is whether Krystal Biotech's current valuation is adequately supported by the level and trajectory of its earnings.

If you want a reference point for whether Krystal Biotech's earnings driven story feels stretched or reasonable, compare it with 30 high quality undervalued stocks.

Does Krystal Biotech Look Pricey on Earnings?

The P/E ratio works well for Krystal Biotech because investors are focused on how much they are paying for each dollar of current profit. On this lens, the stock trades on roughly 42.3x earnings, which is well above the Biotechs industry average of about 17.3x and higher than the peer group at roughly 35.2x.

The fair multiple implied by the company’s own growth profile, margins, size and risk comes out lower than where the shares change hands today. That leaves Krystal Biotech looking overvalued on an earnings basis compared with what that tailored benchmark would suggest, so anyone considering the stock needs to decide whether its pipeline, competitive moat and balance sheet justify paying that kind of premium for each dollar of profit. Explore the numbers behind Krystal Biotech's P/E valuation.

The Krystal Biotech Narrative: What Would Justify Today's Price?

Narratives for Krystal Biotech pick up where the valuation puzzle leaves off and spell out which earnings, growth and margin paths would need to play out for the current share price to look materially higher or lower in hindsight. Each scenario ties its number to a clear view on how Krystal Biotech's growth, profitability and risks might evolve from here, giving you something concrete to revisit as fresh information comes through.

One of the top community narratives on Krystal Biotech: 10% undervalued

"The expansion of Krystal's pipeline, including near term clinical readouts in lung disease, ophthalmology, oncology, and aesthetics, could drive future revenue growth…"

Discover why this Narrative puts Krystal Biotech at 10% undervalued.

Before you act on Krystal Biotech's valuation, there is one more piece to check

Price multiples tell you what investors pay for Krystal Biotech today, but analyst models sketch where they think earnings could be a few years from now, which gives you a different reference point. Explore where analysts expect Krystal Biotech to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com